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The ability of tumor-reactive CD8+ T cells to eradicate
tumors following adoptive transfer of autologous tumor-
infiltrating lymphocytes correlates with their capacity to
proliferate and persist for long periods of time. These qua-
lities are found predominantly in naive and less differen-
tiated memory cells including memory stem cells (TSCM)
and central memory cells (TCM), but the metabolic control
of differentiation remains unknown. Identification of dis-
tinct functional T cell subsets has historically relied on cell
surface markers. Here, we show that combining such
immunophenotyping approaches with an assessment of
mitochondrial activity enables significant enrichment of
stem cell-like T cell populations with enhanced in vivo
biological activity. Upon antigenic stimulation, naïve CD8+
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Figure 1 Degree of autoimmune-induced vitiligo 300 days after adoptive transfer of low TMRM (left) and high-TMRM (right) CD8+
T cells
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T cells divert their bioenergetic metabolism from oxidative
phosphorylation to aerobic glycolysis. Enforcing glycolytic
metabolism by overexpressing the glycolytic enzyme phos-
phoglycerate mutase-1 (PGAM-1) severely impaired the
ability of CD8+ T cells to form long-term memory. Con-
versely, activation of CD8+ T cells in the presence of an
inhibitor of glycolysis, 2-deoxyglucose, enhanced the gen-
eration of memory cells and antitumor functionality.
Furthermore, using TMRM, a fluorescent dye that mea-
sures mitochondrial potential in T cells, we found that
mitochondrial membrane potential (MP) and reactive oxy-
gen species in T cells critically control T cell longevity.
Cells with lower membrane potential (’low MP’) had a
molecular profile characteristic of stem-cell memory pre-
cursors and displayed an enhanced ability to enter the
memory pool as compared to cells displaying higher mito-
chondrial potential (’high MP’) characteristic of short-lived
effectors. Global metabolomic and functional studies
revealed that ‘low MP’ cells exhibited increased levels of
intracellular free fatty acid metabolites, increased expres-
sion of CPT-1a, a rate limiting enzyme involved in fatty
acid oxidation and increased mitochondrial spare respira-
tory capacity, a metabolic property characteristic of long
lived memory T cells. In comparison, ‘high MP’ T cells
displayed enhanced lactate production. Most importantly,
we observed a 100 fold increase in the frequency of sec-
ondary memory CD8+ T cells 300 days after adoptive
transfer of ‘low MP’ as compared to ‘high MP’ T cells. In
tumor-bearing mice, ‘low MP’ cells exhibited increased
cytokine functionality and resulted in the regression of
large, vascularized tumors. Our findings therefore establish
low ΔΨm as a hallmark of stem cell-like behavior and pro-
vide a simple, general and robust enrichment strategy
based on intrinsic cellular metabolism that could have
widespread applications in both regenerative medicine and
to improve T cell based immunotherapy for cancer.
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